Successful etanercept therapy for refractory sacroiliitis in a patient with ankylosing spondylitis and mixed connective tissue disease.

Abstract

The concurrence of ankylosing spondylitis (AS) in a patient with mixed connective tissue disease (MCTD) is rarely described in the literature. Significant and sustained efficacy with tumor necrosis factor (TNF)-alpha blockers has been demonstrated in AS patients. However, evidence to date has revealed associated side effects, including antinuclear antibody induction and development of a lupus-like syndrome. Several authors have reported lupus-like manifestations in MCTD patients treated with TNF-alpha blockers used to control peripheral polyarthritis. In our case report, we demonstrate a good response to etanercept therapy for refractory sacroiliitis in a patient with coexisting AS and MCTD, without development of a lupus-like syndrome. This demonstrates that etanercept therapy may be an appropriate therapeutic agent for sacroiliitis in MCTD patients, as it is in AS alone.

• Authors: Jee Young Lee, Hyun Kyu Chang, Seong-Kyu Kim
• Journal: Yonsei medical journal (Yonsei Med J) Vol. 49 Issue 1 Pg. 159-62 (Feb 29 2008) ISSN: 0513-5796 [Print] Korea (South)
• PMID: 18306484 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Etanercept

Topics

• Etanercept
• Female
• Humans
• Immunoglobulin G (therapeutic use)
• Magnetic Resonance Imaging
• Middle Aged
• Mixed Connective Tissue Disease (complications, drug therapy, pathology)
• Receptors, Tumor Necrosis Factor (therapeutic use)
• Sacroiliac Joint (drug effects, pathology)
• Spondylitis, Ankylosing (complications, drug therapy, pathology)
• Treatment Outcome